Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Scyx crawled time : 13:00 save search
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -1.79%
H: 2.27%
C: -18.18%
financial update results
Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer
Published: 2022-10-25 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.0%
H: 6.75%
C: 5.41%
ATHX | $0.1018 -40.86% 95M
|
Health Technology
|
| O: -0.97%
H: 4.88%
C: -1.95%
biopharma financial
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Published: 2022-10-24 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -7.11%
ongoing infections positive study fungal infection
SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15
Published: 2022-08-09 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.69%
H: 1.03%
C: -7.53%
report update results
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 1.58%
H: 12.84%
C: 7.0%
meeting infections positive study
SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME®
Published: 2022-08-01 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -0.43%
H: 6.09%
C: 5.22%
brexafemme drug application review food
SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections
Published: 2022-08-01 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -0.43%
H: 6.09%
C: 5.22%
brexafemme drug application infections review food
SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections
Published: 2022-06-08 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.4%
H: 9.74%
C: 6.03%
brexafemme drug application infections food submission
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published: 2022-05-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -7.98%
H: 3.06%
C: 1.02%
ongoing positive phase 3
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published: 2022-05-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: -4.04%
ongoing phase 3
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
Published: 2022-04-19 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -0.31%
H: 2.48%
C: 1.55%
brexafemme insurance
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections
Published: 2022-02-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
positive results positive infection phase 3 infections
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Published: 2022-02-10 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
approval positive results potential positive infection phase 3 submission infections
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-11-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 3.57%
H: 0.0%
C: -4.71%
financial results results
SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.95%
H: 3.58%
C: 2.83%
disease treatment infectious disease results phase 3 trial trial results injection infections
SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences
Published: 2021-10-13 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -0.56%
H: 3.49%
C: 3.4%
clinical trials therapy trials phase 3 trial conference injection infections
SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat Mucormycosis
Published: 2021-10-11 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -1.54%
H: 6.57%
C: 5.1%
potential preclinical pre-clinical
SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting
Published: 2021-10-07 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.81%
H: 5.32%
C: 3.82%
ongoing
SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp
Published: 2021-09-29 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.73%
H: 0.36%
C: -3.26%
fungal infections injection infections fungal infection
SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections
Published: 2021-09-23 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: -1.75%
fungal infections phase 3 trial injection infections fungal infection
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.